Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- GSK Japan Foresees 5% Annual Growth by 2026: President Lirette
July 28, 2022
- Horizon Japan Eager for Solo Sales of Its 1st Product as Tepezza Trial Likely to Wrap Up Next Year
July 27, 2022
- Padcev/Keytruda Combo Delivers Positive PIb/II Topline Data for Bladder Cancer: Astellas
July 27, 2022
- Shionogi Launches 4th-Dose COVID Jab Trial for Ages 60-Plus
July 27, 2022
- Mitsubishi Tanabe to Terminate Human Serum Albumin Business
July 26, 2022
- Enhertu Gets FDA’s Priority Review for HER2 Low Breast Cancer
July 26, 2022
- BMS Has High Hopes on Eliquis Follow-Up with Less Bleeding Risks as Patent Loss Looms
July 26, 2022
- Takeda’s Hyqvia Smashes Primary Goal in Global PIII for CIDP
July 25, 2022
- Otsuka Gets EU Panel Backing for Lupus Nephritis Drug
July 25, 2022
- Keytruda, Opdivo, Tagrisso Breach 100 Billion Yen Sales Mark in FY2021: Tally
July 22, 2022
- Daiichi Sankyo Launches Global PII to Test ADC DS-7300 for SCLC
July 22, 2022
- Chugai Enjoys Big Surge in H1 Earnings on Strong Uptake of New Launches
July 22, 2022
- Shionogi to Steadily Promote PIII Trial for COVID Pill after Approval Setback
July 22, 2022
- Gene Therapy VB-111 Fails in PIII Ovarian Cancer Trial: NanoCarrier
July 21, 2022
- JT’s Tapinarof Cream Safe and Effective for Eczema: Japan PIII Study
July 21, 2022
- Texas Court Favors Seagen in Enhertu Patent Row, Daiichi Sankyo Poised to Challenge Ruling
July 21, 2022
- Healios to Raise 2.9 Billion Yen for R&D of eNK Cells
July 20, 2022
- Ono Sets Up Venture Capital Unit to Invest in Digital Health
July 20, 2022
- Opdivo Approved in Taiwan for Frontline Esophageal Cancer Use
July 20, 2022
- Enhertu Gets 2nd Line Breast Cancer Nod in Europe: Daiichi Sankyo
July 20, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…